S4 Medical completes Series A financing
CLEVELAND, April 2, 2021 / PRNewswire / – S4 Medical Takes One More Step in Developing Most Comprehensive Solution to Protect Esophagus from Thermal Injury During Atrial Fibrillation (AF) Catheter Ablation Procedures With Closure of Funding Series A. Three new shareholders – Jobs Ohio, Angel Physician Fund and an anonymous strategic investor – have joined existing investors, to help accelerate marketing efforts.
The Series A funding will primarily be used to conduct the company’s investigative device exemption study, which is expected to begin in July 2021. The company has already taken several important steps, including the first human tests, securing intellectual property and demonstrating compatibility with electrophysiology systems.
S4 Medical was co-founded by Dr. Emile Daoud of Ohio State University, and William fuller. The main product of the company is the resolution catheter – a patented device designed to safely deflect and protect the esophagus during catheter ablation for AF.
Co-founder, chief medical officer, co-inventor of the device and head of the electrophysiology section at The Ohio State University, Emile Daoud, MD, says, “We are delighted with the closing of this investment and excited to begin our pivotal trials. If successful, the resolution The device will be welcomed by electrophysiologists as an added benefit for the management of patients undergoing AF ablation. “
Since its inception in late 2017, S4 has evolved rapidly and taken important steps to bring the resolution device on the market. “S4 offers a world-class solution to a big problem and a big market opportunity,” says co-founder and CEO William fuller. “Our existing and new investors see the promise of the S4 solution and the potential to provide additional safety to catheter ablation procedures.”
“We immediately recognized the value of S4’s technology and are delighted not only to participate in this funding, but also to support S4 in its clinical studies,” says Manish bhandari, MD, Managing Partner of the Angel Physician Fund of Cincinnati, who comes into the cycle with a wealth of clinical and entrepreneurial experience.
Member of the board of directors of S4 and general manager of Columbus-Founded for Ohio Innovation (OIF), Bill Baumel, adds: “The OIF reinvests with confidence in S4 Medical and its mission of commercializing cutting-edge research, with the aim of having a considerable positive impact on people’s lives.
“AF ablation is a large and rapidly growing market,” says Hardik desai, senior partner at Jumpstart Inc, from Cleveland, Ohio, “and we are pleased to support S4 as they enter the clinical phase to commercialization to address this critical unmet need.” Jumpstart, which focuses on early stage investing and has been involved in S4 from the start, has also reinvested in the Series A cycle.
S4 Medical Corp. is a medical device company specializing in innovative solutions for cardiac procedures. The main goal of the company is a simple but comprehensive solution to reduce complications of the esophagus during catheter ablation treatment for atrial fibrillation. The S4 team is driven by providing advanced solutions for superior healthcare. For more information visit S4 at www.S4medical.com on LinkedIn and Twitter.
SOURCE S4 Medical